What are the real benefits of Wegovy — and is it the right decision for you?

The weight-loss benefit the trials actually measured

Most people searching for the benefit of Wegovy want a straight answer on results. Here it is: in the STEP 1 trial published in the New England Journal of Medicine, adults with obesity who took semaglutide 2.4mg weekly alongside lifestyle support lost an average of around 15% of their body weight over 68 weeks. The placebo group, who also received lifestyle support, lost roughly 2.4%. That gap is the clinical signal.

What the headline figure doesn't show is the distribution. Some participants lost considerably more; others less. Weight loss on any medicine is shaped by starting weight, adherence, diet, activity and individual biology. Wegovy's job is to reduce appetite by mimicking a gut hormone that signals fullness to the brain, which makes it easier to eat less consistently over time. It doesn't override lifestyle; it works alongside it. If you want to read more about how semaglutide works in the body, that page goes into the mechanism in detail.

For context on how those results compare between the two licensed weight-loss injections, the semaglutide weight-loss benefits page covers the evidence side by side. A prescriber will factor in your individual circumstances before recommending which medicine, if any, is the right fit.

Benefits that sit alongside weight loss

Weight reduction is the licensed purpose, but the trials captured other changes worth understanding. In STEP 1 participants, meaningful improvements were seen in blood pressure readings, fasting blood glucose, HbA1c and lipid profiles as body weight fell. These aren't incidental, they're part of why NICE and NHS England consider the medicine clinically significant for people whose weight is contributing to conditions like hypertension or prediabetes.

Wegovy also holds a separate UK authorisation for reducing the risk of major cardiovascular events in eligible adults, which is distinct from its weight-management licence. That authorisation matters because it reflects a body of evidence beyond the scales. If you're interested in the full range of benefits Wegovy is associated with, that page covers the cardiovascular and metabolic picture in more depth.

Men sometimes ask whether the benefit profile looks different for them. The short answer is that the weight-loss evidence is consistent across sexes, though body-composition changes can differ. Wegovy's benefits for men explores what the trial data shows for male participants specifically. And if you're comparing semaglutide's broader effects, the semaglutide benefits overview draws together the evidence across indications.

Who the benefit is most likely to apply to, and who it won't suit

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 where at least one weight-related health condition is present, such as high blood pressure, type 2 diabetes or raised cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. That's the licensed starting point, but eligibility is only half the picture.

A prescriber also considers your medical history before approving treatment. Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It's not licensed for under-18s. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 means it won't be prescribed, and a history of pancreatitis requires careful discussion. The most common side effects are gastrointestinal (nausea, vomiting, constipation, diarrhoea) typically most noticeable when starting or after a dose increase, and usually settling over days to a couple of weeks. The NHS semaglutide medicines page sets out the full side-effect and contraindication list in plain language.

For practical detail on how to access Wegovy through a regulated route in the UK, this page on where to buy Wegovy explains what to look for and how to verify a pharmacy. Wegovy is a prescription-only medicine, so any seller offering it without a clinical assessment is a red flag worth taking seriously.

Deciding whether the benefit justifies starting treatment

If you've read this far, you're probably not asking a simple question. Many people who land on this page have already tried other approaches (lower-calorie eating, exercise programmes, earlier interventions) and are asking whether semaglutide would actually move the needle for them. That's a legitimate clinical question, not a vanity one.

The honest answer is that no page can tell you what your individual benefit will be. What the evidence does show is that for many adults with obesity or a weight-related health condition, Wegovy produces clinically meaningful weight loss that lifestyle change alone rarely matches. The benefits of taking semaglutide page goes deeper on what that means in practice across different starting situations.

Our prescribers review every consultation personally, the same day you submit it. They look at your full health picture, not just your BMI. If Wegovy is clinically suitable, treatment is dispatched the same day for free next-working-day delivery. If it isn't right for you, they'll say so. You can also explore all available weight-loss treatment options to understand what else is licensed and how each compares. When you're ready to talk it through, speak to our prescribers through a free consultation, no obligation, and reviewed the same day.